Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Immunology, Immunotherapy
Published in: Cancer Immunology, Immunotherapy 6/1999

01-03-1999 | ORIGINAL ARTICLE

Humanisation and characterisation of PR1A3, a monoclonal antibody specific for cell-bound carcinoembryonic antigen

Authors: Lorna M. Stewart, Susan Young, Graham Watson, Stephen J. Mather, Paul A. Bates, Heather A. Band, Robert W. Wilkinson, Elizabeth L. Ross, David Snary

Published in: Cancer Immunology, Immunotherapy | Issue 6/1999

Login to get access
Metadata
Title
Humanisation and characterisation of PR1A3, a monoclonal antibody specific for cell-bound carcinoembryonic antigen
Authors
Lorna M. Stewart
Susan Young
Graham Watson
Stephen J. Mather
Paul A. Bates
Heather A. Band
Robert W. Wilkinson
Elizabeth L. Ross
David Snary
Publication date
01-03-1999
Publisher
Springer-Verlag
Published in
Cancer Immunology, Immunotherapy / Issue 6/1999
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s002620050534

Other articles of this Issue 6/1999

Cancer Immunology, Immunotherapy 6/1999 Go to the issue

ORIGINAL ARTICLE

Autoantibodies against the tumour-associated antigen GA733-2 in patients with colorectal carcinoma

SYMPOSIUM SERIES

Cancer Vaccine Week, an international symposium 5–9 October 1998, New York, NY

ORIGINAL ARTICLE

Comparison of simian virus 40 large T antigen recombinant protein and DNA immunization in the induction of protective immunity from experimental pulmonary metastasis

ORIGINAL ARTICLE

Kinetics of cellular trafficking and cytotoxicity of 9.2.27-gelonin immunotoxins targeted against the high-molecular-weight melanoma-associated antigen

ORIGINAL ARTICLE

Effect of local interleukin-2 treatment on spontaneous tumours of different immunogenic strength

ORIGINAL ARTICLE

Vaccination with the extracellular domain of p185 neu prevents mammary tumor development in neu transgenic mice
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits